通过氨酸受体稳定蛋白calstabin2保护心律失常
Xander H T Wehrens1, Stephan E Lehnart, Steven R Reiken
1Department of Physiology and Cellular Biophysics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Science (New York, N.Y.)
|April 10, 2004
概括
由于心室节律失常的突然心脏死亡可以预防. 使用JTV519稳定calstabin2蛋白与RyR2通道的相互作用,阻止导致致命心律的泄漏.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心室节律失常是不同患者群体突然心脏死亡 (SCD) 的主要原因.
- 从氨酸受体-释放通道 (RyR2) 综合体中消耗calstabin2 (FKBP12.6) 会导致细胞内 (Ca2+) 泄漏,引发致命的心律失常.
- 这种现象在心力衰竭模型和运动诱导的SCD遗传形式中观察到.
研究的目的:
- 为了研究稳定calstabin2-RyR2相互作用的治疗潜力.
- 为了评估JTV519的疗效,一个1,4-西胺衍生物,在预防心律失常.
主要方法:
- 利用心力衰竭的动物模型和对患有遗传性运动诱导性SCD的患者的研究.
- 评估了JTV519对RyR2复合物的calstabin2亲和力的影响.
- 监测细胞内Ca2+泄漏和心律不整的发生.
主要成果:
- JTV519显著增加了calstabin2与RyR2的结合亲和力.
- 这种稳定性防止了异常的细胞内Ca2+泄漏.
- 治疗有效地抑制了致命心律失常的触发.
结论:
- 加强calstabin2与RyR2的结合是一种有前途的治疗策略.
- 准calstabin2-RyR2复合体可能为管理常见心室节律失常和预防SCD提供一种新的方法.
相关概念视频
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:28Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
01:16Calmodulin-dependent Signaling
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...